Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM3 | Q14832 | 2/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053307 | 0.89 | GRM3 (0.56) | GRM3FOLH1 | |
| SCHEMBL5052935 | 0.88 | GRM3 (0.55) | GRM3FOLH1 | |
| SCHEMBL5051106 | 0.88 | GRM3 (0.55) | GRM3FOLH1 | |
| SCHEMBL5053061 | 0.88 | GRM3 (0.55) | GRM3FOLH1 | |
| SCHEMBL5057972 | 0.88 | GRM3 (0.55) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5057821 | 0.87 | GRM3 (0.51) | GRM3FOLH1 | |
| SCHEMBL5054377 | 0.86 | GRM3 (0.50) | GRM3FOLH1 | |
| SCHEMBL5133546 | 0.86 | GRM3 (0.50) | GRM3FOLH1 | |
| SCHEMBL7050804 | 0.86 | GRM3 (0.50) | GRM3FOLH1 | |
| SCHEMBL5057846 | 0.86 | GRM3 (0.50) | GRM3FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1066297-B1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2002-10-23 | — | — | EP | claimed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002509934-A | — | — | 2002-04-02 | — | — | JP | claimed |
| EP-1066297-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2001-01-10 | — | — | EP | claimed |
| US-6121252-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME INHIBITORS TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-09-19 | — | — | US | claimed |
| WO-1999050272-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-07 | — | — | WO | claimed |
| US-20210188979-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making and Using Same | PFIZER INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210177857-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME | PFIZER INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-10952972-B2 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | PFIZER INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3511019-B1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20200093827-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | PFIZER INC. (US) | 2020-03-26 | — | — | US | disclosed |
| EP-2774608-B1 | Drug loaded polymeric nanoparticles and methods of making and using same | PFIZER (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190269617-A1 | Methods of Controlling Morphology of Polymeric Nanoparticles | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| EP-1093453-A1 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-2001001974-A2 | NAALADASE INHIBITORS IN ANXIETY AND MEMORY DISORDERS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| EP-1066297-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2001-01-10 | — | — | EP | disclosed |
| US-6121252-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME INHIBITORS TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-09-19 | — | — | US | disclosed |
| WO-2000038785-A2 | METHODS FOR TREATING CERTAIN DISEASES USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000001668-A2 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999050272-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188979-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making and Using Same | CD47, CD274, PDCD1 | GRM3 1415/4885FOLH1 8/4885NAALAD2 869/4885 |
| US-20190269617-A1 | Methods of Controlling Morphology of Polymeric Nanoparticles | CLTB, NCL, ACTB | GRM3 3686/4885FOLH1 828/4885NAALAD2 3320/4885 |
| US-10952972-B2 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | CTSA, GAA, EEA1 | GRM3 3516/4885FOLH1 135/4885NAALAD2 1736/4885 |
| US-20200093827-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | MTHFD1, TYMP, FPGS | GRM3 3406/4885FOLH1 51/4885NAALAD2 3323/4885 |
| US-20210177857-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME | TP53, HNRNPH3, VHL | GRM3 3261/4885FOLH1 336/4885NAALAD2 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.